FDA Grants Breakthrough Device Designation for nQ Medical’s neuroQWERTY

FDA Grants Breakthrough Device Designation for nQ Medical’s neuroQWERTY
The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to nQ Medical’s neuroQUERTY software, which is designed to monitor brain health and Parkinson’s disease progression. Breakthrough device status is given to medical devices that have the potential to be an effective treatment or diagnostic tool for life-threatening or irreversibly debilitating diseases. The status speeds the review and assessment ... read more
Source: Parkinson’s News TodayPublished on 2020-02-11By Charlotte Baker